Key Highlights

● BDX closed at $183.69 on 9 October 2026, and the $185.07 consensus target implies upside of only about 0.8%.

● The consensus draws on 17 analysts, with targets from $150 to $210, while the second data set shows a higher $194.08 mean from 15 analysts.

● Market data shows seven Buy, nine Hold and one Sell rating, a Hold consensus.

● Barclays initiated coverage with a $165 target on 7 October, the newest broker action and below the share price.

Becton, Dickinson and Company (NYSE:BDX), the medical technology group and a member of the S&P 500, closed at $183.69 on Friday 9 October 2026, with the consensus analyst target barely above the share price.

What Is the Latest Analyst Price Target?

Market data shows a consensus target of $185.07 from 17 analysts over 12 months, with a high of $210 and a low of $150. That implies upside of only about 0.8% from the $183.69 close. The second data set, using third-party data, shows a higher mean of $194.08, a median of $195, a high of $225 and a low of $165 from 15 analysts. The named broker targets published over the past three months average roughly $186, which fits the first figure better.

What Are Wall Street Analysts Saying?

Market data records seven Buy ratings, nine Hold and one Sell, a Hold consensus. The second data set shows seven Buy or Strong Buy, seven Hold and one Sell.

Recent named actions point to a divided panel. Barclays initiated coverage on 7 October with a target of $165. Bank of America raised its target from $185 to $200 on 31 August with a Neutral rating. Citigroup reiterated Buy on 13 August, and Royal Bank of Canada lifted its target from $180 to $190 at Sector Perform. In early August Stifel set a $195 target, Piper Sandler raised its target from $161 to $175 and Wells Fargo from $161 to $170, while Jefferies reiterated Buy at $210 and TD Cowen raised from $163 to $182 with a Hold rating. UBS initiated at Buy with a $190 target on 28 July.

What Could Help the Stock Reach the Price Target?

Because the consensus sits barely above the share price, the target does not require a large move. Market data cites earnings per share of $3.23 against $3.14 expected and revenue of $4.98 billion against $4.89 billion.

What Could Prevent the Stock Reaching the Target?

The range of targets is wide, from $150 to $210 on market data. The newest broker action, Barclays at $165, sits below the share price's current level of around $184, and the lowest published target, $150 from Goldman Sachs on 27 May, is also below it. A Hold-heavy panel suggests limited conviction, and medical device makers can be affected by hospital spending, product recalls, regulation and currency movements. The consensus target suggests little upside, so the shares would need positive surprises to push analysts higher.

What Should Investors Watch Next?

Further analyst target changes, progress on the manufacturing partnership, and updates on new products will be watched.

Becton Dickinson's Near-Zero Target Gap Leaves Little Room for Error

Becton Dickinson closed at $183.69 on 9 October 2026, with the $185.07 consensus target only about 0.8% higher and the second data set's $194.08 mean implying somewhat more. Named targets published over the past three months average roughly $186 and range from Barclays' new $165 to Jefferies' $210, while the lowest published target, $150 from Goldman Sachs on 27 May, is also below the share price. A Hold-heavy panel suggests limited conviction, and market data shows earnings per share of $3.23 against $3.14 expected.